Tests IB-T101 injection in adults with advanced kidney cancer
Tests IB-T101 injection in adults with advanced clear cell kidney cancer.
Plain-language title generated from the registry record
Registry title: IB-T101 Injection for Treatment of Patients With Advanced Clear Cell Renal Cell Carcinoma
Key facts
- Where
- Wuhan, ChinaSee the site
- Phase
- Phase 1
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with advanced clear cell renal cell carcinoma (a type of kidney cancer) to test the safety and effect of IB-T101 injection.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Advanced clear cell renal cell carcinoma
Main reasons for not taking part
- Serious brain or nervous system problems, such as seizures, stroke or dementia
- Any immune system weakness, including known HIV infection
- Heart attack or unstable angina in the past 6 months
- Fluid around the lungs that needed draining in the past 28 days
Read by machine on 12 November 2026.
Where in China
- Tongji Hospital, Huazhong University of Science and TechnologyWuhan, ChinaContact: Bo LiuTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Grit Biotechnology
- Trial code
- NCT06819293
- Record updated
- 14 April 2026
- Original description
This is an open label, single center, dose escalation, and dose extension IIT study aimed at evaluating the safety, efficacy, and pharmacokinetics of IB-T101 in adult patients with advanced clear renal cell carcinomaRead full original descriptionShow less
A Phase I, Open Label, Single Center Study Evaluating the Safety and Efficacy of IB-T101 Injection for Treatment of Patients With Advanced Clear Cell Renal Cell Carcinoma
This is an open label, single center, dose escalation, and dose extension IIT study aimed at evaluating the safety, efficacy, and pharmacokinetics of IB-T101 in adult patients with advanced clear renal cell carcinoma
Inclusion: Voluntarily join the study, signed informed consent form， willing and able to comply with the study protocol; Age ≥18 years old; Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1; Expected survival time of ≥ 3 months.
Exclusion: Have experienced myocardial infarction or unstable angina within the 6 months prior to screening; Pleural effusion requiring drainage for symptom management within 28 days prior to screening; CNS dysfunction with clinical significance. For example, seizures, cerebral ischemia/hemorrhage, dementia, cerebellar diseases, cerebral edema, reversible posterior encephalopathy syndrome, or any autoimmune disease involving the CNS; Any form of primary and acquired immunodeficiency (such as severe combined immunodeficiency). Known human immunodeficiency virus (HIV) positive subjects.